Journal of Immunotherapy and Precision Oncology (May 2024)

Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy

  • Khalid Jazieh,
  • Lisa Kottschade,
  • Anastasios Dimou

DOI
https://doi.org/10.36401/JIPO-23-44
Journal volume & issue
Vol. 7, no. 2
pp. 126 – 129

Abstract

Read online

ABSTRACT: Despite ocular adverse events from immune checkpoint inhibitors being uncommon, they are still important complications to be aware of. We present the case of metastatic melanoma on ipilimumab/nivolumab in a patient who developed immunotherapy complications with delayed diagnosis because the only presenting symptom was unilateral ptosis. We reviewed the literature for relevant and important ocular and neurological complications of immune checkpoint inhibitors.

Keywords